Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Cellectar Biosciences (NASDAQ: CLRB)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on vTv Therapeutics (VTVTResearch Report) and Cellectar Biosciences (CLRBResearch Report) with bullish sentiments.

vTv Therapeutics (VTVT)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on vTv Therapeutics, with a price target of $5. The company’s shares closed last Monday at $1.26, close to its 52-week low of $0.68.

Bernardino commented:

“Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows from annual sales and royalty payments of azeliragon and TPP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success.”

According to TipRanks.com, Bernardino has 0 stars on 0-5 star ranking scale with an average return of -6.9% and a 29.1% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Innovus Pharmaceuticals Inc, ENDRA Life Sciences Inc, and Cassava Sciences Inc.

vTv Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, implying a 411.8% upside from current levels. In a report issued on August 1, Northland Securities also assigned a Buy rating to the stock with a $8 price target.

See today’s analyst top recommended stocks >>

Cellectar Biosciences (CLRB)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Cellectar Biosciences, with a price target of $3. The company’s shares closed last Monday at $2.12.

Ramakanth noted:

“We maintain our Buy rating and adjust our 12-month price target to $3.00 per share, down from $4.00. We derive our price target based on a risk-adjusted NPV (rNPV) analysis of projected CLR131 revenues through 2029 assuming a 12.6% discount rate and a 2% terminal growth rate. We derive an rNPV of $148M for the product and add in cash and cash equivalents of $16.8M to arrive at a 12-month price target of $2.98 per diluted share, which we round to $3.00. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.”

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -12.4% and a 26.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cellectar Biosciences with a $4.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.